Contact
searchSearch
HMP Global

Follicular Lymphoma Topic Center

News
Long-Term Follow-up Confirms Durable Responses With Epcoritamab in R/R LBCL
03/30/2026
Lisa Kuhns, PhD, MD
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab...
03/30/2026
First Report Managed Care
News
CD3/CD20 Bispecific T-cell Engagers Show High Response Rates in Follicular Lymphoma
03/26/2026
Lisa Kuhns, PhD, MD
Bispecific CD3/CD20 T-cell engagers deliver striking response rates with manageable safety in follicular lymphoma, positioning them as a potential game-changer in earlier lines of therapy.
Bispecific CD3/CD20 T-cell engagers deliver striking response rates with manageable safety in follicular lymphoma, positioning them as a potential game-changer in earlier lines of therapy.
Bispecific CD3/CD20 T-cell...
03/26/2026
First Report Managed Care
News
Patient Outcomes After Epcoritamab or Glofitamab Failure in R/R LBCL
03/25/2026
Grace Taylor, MS, MA
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with rapid relapse and poor survival outcomes, highlighting a critical unmet need for...
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with rapid relapse and poor survival outcomes, highlighting a critical unmet need for...
Disease progression after...
03/25/2026
First Report Managed Care
News
CAR T-Cell Therapy and Bispecific Antibodies Diverge in Relapsed or Refractory DLBCL
03/25/2026
Hannah Musick
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory...
03/25/2026
First Report Managed Care
News
Epcoritamab Triplet Improves Response and Survival in Relapsed or Refractory Follicular Lymphoma
03/24/2026
Lisa Kuhns, PhD, MD
Epcoritamab added to lenalidomide and rituximab markedly improves response rates and progression-free survival in relapsed or refractory follicular lymphoma, emerging as a potential new chemotherapy-free standard of care.
Epcoritamab added to lenalidomide and rituximab markedly improves response rates and progression-free survival in relapsed or refractory follicular lymphoma, emerging as a potential new chemotherapy-free standard of care.
Epcoritamab added to...
03/24/2026
First Report Managed Care
News
Older Adult Data Underreported in DLBCL Registration Trials Worldwide
03/18/2026
Hannah Musick
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse large B-cell lymphoma (DLBCL) registration trials found that while most primary outcomes are reported for older adults, key data on secondary endpoints, toxicity, and quality of life remain largely missing,...
A systematic review of diffuse...
03/18/2026
First Report Managed Care
News
Fixed-Duration Epcoritamab Plus R2 Shows Strong Outcomes in R/R Follicular Lymphoma
03/17/2026
Grace Taylor, MS, MA
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab combined with rituximab plus lenalidomide (R2) delivers high complete response rates and durable remissions in relapsed or refractory (R/R) follicular lymphoma, according to a study published in Blood.
Fixed-duration epcoritamab...
03/17/2026
First Report Managed Care
News
Single Bispecific Antibody Use May Reduce Costs and Streamline Lymphoma Care
03/12/2026
Lisa Kuhns, PhD, MD
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody used across multiple lymphoma indications could save oncology practices hundreds of thousands of dollars and thousands of staff hours annually, according to a new mixed-methods analysis published in Future...
A single bispecific antibody...
03/12/2026
First Report Managed Care
News
Epcoritamab Shows Superior Responses vs Chemoimmunotherapy in Relapsed Follicular Lymphoma
03/11/2026
Hannah Musick
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of third-line or later follicular lymphoma, epcoritamab demonstrated significantly higher response rates vs chemoimmunotherapy and favorable safety compared with other bispecific antibodies.
In an indirect comparison of...
03/11/2026
First Report Managed Care
News
GLOBIN Study Reports Promising First-Line Outcomes in Follicular Lymphoma
03/06/2026
Grace Taylor, MS, MA
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus...
03/06/2026
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos

What's New?

News
Long-Term Follow-up Confirms Durable Responses With Epcoritamab in R/R LBCL
03/30/2026
Lisa Kuhns, PhD, MD
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab continues to deliver durable responses and manageable safety in heavily pretreated patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), with sustained remissions seen in a substantial proportion of...
At 3 years, epcoritamab...
03/30/2026
First Report Managed Care
News
CD3/CD20 Bispecific T-cell Engagers Show High Response Rates in Follicular Lymphoma
03/26/2026
Lisa Kuhns, PhD, MD
Bispecific CD3/CD20 T-cell engagers deliver striking response rates with manageable safety in follicular lymphoma, positioning them as a potential game-changer in earlier lines of therapy.
Bispecific CD3/CD20 T-cell engagers deliver striking response rates with manageable safety in follicular lymphoma, positioning them as a potential game-changer in earlier lines of therapy.
Bispecific CD3/CD20 T-cell...
03/26/2026
First Report Managed Care
News
Patient Outcomes After Epcoritamab or Glofitamab Failure in R/R LBCL
03/25/2026
Grace Taylor, MS, MA
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with rapid relapse and poor survival outcomes, highlighting a critical unmet need for...
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with rapid relapse and poor survival outcomes, highlighting a critical unmet need for...
Disease progression after...
03/25/2026
First Report Managed Care
News
CAR T-Cell Therapy and Bispecific Antibodies Diverge in Relapsed or Refractory DLBCL
03/25/2026
Hannah Musick
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR) T-cell therapy shows greater durability and survival benefits, while bispecific antibodies offer lower toxicity and more accessible outpatient...
In relapsed or refractory...
03/25/2026
First Report Managed Care
News
Epcoritamab Triplet Improves Response and Survival in Relapsed or Refractory Follicular Lymphoma
03/24/2026
Lisa Kuhns, PhD, MD
Epcoritamab added to lenalidomide and rituximab markedly improves response rates and progression-free survival in relapsed or refractory follicular lymphoma, emerging as a potential new chemotherapy-free standard of care.
Epcoritamab added to lenalidomide and rituximab markedly improves response rates and progression-free survival in relapsed or refractory follicular lymphoma, emerging as a potential new chemotherapy-free standard of care.
Epcoritamab added to...
03/24/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use